Pictet Asset Management (UK)’s SpringWorks Therapeutics SWTX Stock Holding History

Pictet Asset Management (UK)’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$52.4M	Sell	636,236 -108,999	-15%	-$8.28M	0.06%	330
2021 Q1	$54.8M	Sell	745,235 -119,588	-14%	-$9.37M	0.07%	314
2020 Q4	$62.7M	Buy	864,823 +285,490	+49%	+$18.4M	0.08%	266
2020 Q3	$27.6M	Buy	+579,333	New	+$24.7M	0.04%	375

Other funds holding SWTX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Pictet Asset Management (UK)'s SWTX Position: Q2 2021 in Review

Pictet Asset Management (UK) reduced its SpringWorks Therapeutics (SWTX) stake by 15% in Q2 2021, selling an estimated $8.28M and leaving 636,236 shares worth $52.4M. The position accounts for 0.06% of the portfolio, ranked #330.

Pictet Asset Management (UK) first reported a position in SWTX in Q3 2020 and has held it in 4 quarters since. The position peaked at $62.7M in Q4 2020. 134 funds tracked by Wall St. Rank hold SWTX as of Q2 2021.

Pictet Asset Management (UK) held 636,236 shares of SpringWorks Therapeutics worth $52.4M as of Q2 2021.
Pictet Asset Management (UK) sold 108,999 SpringWorks Therapeutics shares in Q2 2021, an estimated $8.28M.
SpringWorks Therapeutics made up 0.06% of Pictet Asset Management (UK)'s portfolio in Q2 2021, its #330 holding.
Pictet Asset Management (UK) first reported a position in SpringWorks Therapeutics in Q3 2020 and has held it in 4 quarters since.
Pictet Asset Management (UK)'s SpringWorks Therapeutics position peaked at $62.7M in Q4 2020.
134 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2021.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2021, filed 16 Aug 2021.